Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255761 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
A Phase 4 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 736
- Enrollment target
NCT01255761 is a Phase 4 study that has completed, run by UCB Pharma. The registered enrollment target is 736 participants.
The verdict
NCT01255761, a Phase 4 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 736 participants
- Enrollment target
Study Summary
Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
Interventions
- BIOLOGICAL Certolizumab Pegol (CZP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255761
The ClinicalTrials.gov registry entry for NCT01255761 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 736 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol (CZP) is the first listed.
NCT01255761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01255761 about?
NCT01255761 is a clinical study titled "A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects". Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
What is the current status of trial NCT01255761?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 736 participants. The study started on 2010-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01255761?
The interventions under investigation include: Certolizumab Pegol (CZP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01255761?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.